NETHERLANDS

Blastoise: The Official Mascot Meme Coin of Blast - Unveiling the Future of L2 Finance

Retrieved on: 
Monday, March 4, 2024

It stands out in the meme coin space, which is often driven by hype and community engagement.

Key Points: 
  • It stands out in the meme coin space, which is often driven by hype and community engagement.
  • Firstly, the meme coin market is known for repetitive designs, with numerous dog-themed memes flooding the market and needing more imagination.
  • This ensures an active community of users that are invested in its ecosystem beyond the thrill of just owning a meme coin.
  • Lastly, Six weeks after its debut, Blastoise made a significant impact by collaborating with Bitconnect token, the official meme decentralized exchange (DEX) on Blast.

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

Retrieved on: 
Monday, March 4, 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V .

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V .
  • (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 12:00 p.m.
  • The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website.
  • The archived presentation will also be available there for a limited time after the event.

Verizon Connect expands Reveal EV Platform to Europe

Retrieved on: 
Monday, March 4, 2024

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Today, Verizon Connect announced the European expansion of its Reveal EV capabilities in addition to the new Electric Vehicle Suitability Tool.

Key Points: 
  • NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Today, Verizon Connect announced the European expansion of its Reveal EV capabilities in addition to the new Electric Vehicle Suitability Tool.
  • "When our customers speak, we listen, and the introduction of our EV Suitability Tool, as well as our Reveal EV expansion into Europe, is another example of us responding to their needs."
  • Following the success of its U.S. launch, Verizon Connect is expanding its Reveal EV capabilities to European customers including Germany, France, Ireland, Italy, Netherlands, Poland, Portugal, and the United Kingdom.
  • This one way integration pulls data from Verizon Connect Reveal into NextEra Mobility’s software so they can build an electrification plan for customers.

Alimentaria&Hostelco 2024 will have record international participation

Retrieved on: 
Monday, March 4, 2024

BARCELONA, Spain, March 04, 2024 (GLOBE NEWSWIRE) -- The leading international business platform for food, beverages, food service and hospitality equipment will return to Fira de Barcelona's Gran Via exhibition center (Spain) from 18 to 21 March 2024, with a 15% increase in the number of foreign exhibitors compared to the previous edition. Of the 3,200 exhibiting companies, 900 will be international.

Key Points: 
  • Of the 3,200 exhibiting companies, 900 will be international.
  • Alimentaria&Hostelco 2024, which will bring together a high-quality, cross-cutting range of products and services, will beat its record for internationalization.
  • In this edition, business opportunities for the Horeca channel in the international sphere, especially in Europe, will be further boosted.
  • Some 100,000 trade visitors are expected, 25% of them international.

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Retrieved on: 
Monday, March 4, 2024

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.

Key Points: 
  • Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.
  • CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 - 6, 2024, in Boston, MA.
  • Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 16 - 17, 2024, in Amsterdam, The Netherlands.
  • VLA15, the Company’s Lyme disease vaccine candidate, is currently in Phase 3 clinical development and partnered with Pfizer for this study and global commercialization.

ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA

Retrieved on: 
Thursday, February 29, 2024

This is the tenth FDA BDD awarded to ONWARD Medical.

Key Points: 
  • This is the tenth FDA BDD awarded to ONWARD Medical.
  • The designation is reserved for novel, cutting-edge therapies addressing an unmet need and provides many potential regulatory and reimbursement advantages.
  • This latest award gives ONWARD Medical priority FDA review, the opportunity to interact with FDA experts throughout the pre-market regulatory review phase, and the potential to seek additional reimbursement for its ARC-BCI System.
  • “Brain-computer interface technology unlocks the transformative potential to enhance ARC-IM with thought-driven control of movement after paralysis,” said ONWARD Medical CEO Dave Marver.

Bringing confident diagnosis to more patients at low cost: Philips launches new AI-enabled CT 5300 at #ECR2024

Retrieved on: 
Thursday, February 29, 2024

The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximizes system up-time, helping to improve patient outcomes and department productivity.

Key Points: 
  • The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximizes system up-time, helping to improve patient outcomes and department productivity.
  • However, a lack of availability of high-quality CT systems, or physicians qualified to read cardiac CT exams, often prevents this approach.
  • The Philips CT 5300 system meets advanced diagnostic imaging requirements for cardiac care patient guidelines, as well as for other challenging areas such as trauma care and interventional procedures.
  • Emphasizing lifetime value and sustainability, the CT 5300 is designed to lower energy consumption.

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, February 29, 2024

“argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • Clinically, we generated significant data through multiple study readouts, achieving key milestones for both the CIDP and MMN patient communities and importantly advancing our second molecule, empasiprubart.
  • Looking forward to 2024, we will act with a continued sense of purpose to expand our patient reach.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Retrieved on: 
Thursday, February 29, 2024

Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.

Key Points: 
  • Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.
  • Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024.
  • To participate in the conference call, please register in advance using the link below.
  • Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.